Boron Neutron Capture Therapy (BNCT) leverages the nuclear reaction between boron-10 and thermal neutrons to selectively destroy cancer cells while minimizing damage to surrounding healthy tissues. This therapy has found use in treating glioblastoma, which as a brain cancer, is difficult to treat using conventional radiotherapy, surgery, and chemotherapy due to location and the risk of brain damage. However, to work, the cells must contain 10B. 4-Borono-l-phenylalanine (l-BPA) is the most frequently used boron delivery agent in this therapy. Surprisingly, despite its seemingly simple structure, there is no consensus approach to making it-the synthesis of l-BPA has been approached through multiple routes, reflecting the challenges in producing high-purity, isotopically enriched material. When a new site is looking to make this essential material, it can be challenging to determine the best route for the situation as there is no critical analysis comparing and discussing the relative merits of the approaches. Herein, we comprehensively and critically examine and compare the reported methods, from both the academic and patent literature, used to synthesize l-BPA. The review also highlights the limitations of each method regarding scalability, cost-effectiveness, and safety, especially considering the high cost of isotopically enriched 10B.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.202500059DOI Listing

Publication Analysis

Top Keywords

boron neutron
8
neutron capture
8
capture therapy
8
isotopically enriched
8
boron
4
boron mind
4
mind comprehensive
4
comprehensive review
4
review evolution
4
evolution diverse
4

Similar Publications

Boron Neutron Capture Therapy (BNCT) leverages the nuclear reaction between boron-10 and thermal neutrons to selectively destroy cancer cells while minimizing damage to surrounding healthy tissues. This therapy has found use in treating glioblastoma, which as a brain cancer, is difficult to treat using conventional radiotherapy, surgery, and chemotherapy due to location and the risk of brain damage. However, to work, the cells must contain 10B.

View Article and Find Full Text PDF

Anaplastic thyroid cancer (ATC) is the rarest and most aggressive form of thyroid cancer, known for its highly variable nature and poor prognosis, primarily due to the lack of effective treatments. While conventional therapies have had limited success, there remains an urgent need for novel therapeutic approaches to combat this disease. ATC tumors are resistant to the standard radioiodine therapy because they lack the sodium/iodide symporter (NIS), which is necessary for iodine uptake.

View Article and Find Full Text PDF

Purpose: The micro-distribution of boron compounds within cells influences the effectiveness of boron neutron capture therapy (BNCT) in killing tumor cells. Boron neutron capture therapy-sensitive organelles within the range of α particles and Li recoil nuclei can enhance killing effects on tumor cells. However, comprehensive studies on the sensitive organelles to BNCT are currently lacking.

View Article and Find Full Text PDF

Development of an affine transformation based treatment control system for accelerator based boron neutron capture therapy.

Rev Sci Instrum

March 2025

Frontiers Science Center for Rare Isotopes, Lanzhou University, 730000 Lanzhou, China and School of Nuclear Science and Technology, Lanzhou University, 730000 Lanzhou, China.

This study developed and validated an adaptive treatment control system based on affine transformation for accelerator-based boron neutron capture therapy. Accelerator-based boron neutron capture therapy is a form of targeted radiotherapy that uses boron-10 to label tumor cells. When these boron-rich cells interact with neutrons, they produce high-linear energy transfer alpha particles and lithium-7 particles, effectively destroying the tumor cells with precision.

View Article and Find Full Text PDF

The Impact of Prostate-Specific Antigen and Gleason Scores on Cardiovascular Death in Prostate Cancer Patients after Radiotherapy or Chemotherapy: A Population-Based Study.

Rev Cardiovasc Med

February 2025

Guangdong Engineering Research Center of Boron Neutron Therapy and Application in Malignant Tumors, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Dongguan Engineering Research Center for Innovative Boron Drugs and Novel Radioimmune Drugs, Cancer Center, The 10th Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Southern Medical University, Guangdong 523059, China.

Background: Tumor characteristics are associated with the risk of cardiovascular death (CVD) in cancer patients. However, the influence of tumor characteristics on CVD risk among prostate cancer (PC) patients who have received radiotherapy (RT) or chemotherapy (CT) is often overlooked. This study explored the association between PC tumor characteristics and CVD risk in PC patients who had received RT or CT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!